Abstract
Among the drugs used in conditioning regimens for stem cell transplantation, high-dose melphalan (HDM) plays an important role for both its strong myeloablative effect and for its favourable dose–response ratio. Here we report five cases of high frequency atrial fibrillation (AF) developing after HDM. Duration of the arrhythmia was always very short, beginning at variable intervals after the administration of HDM, in the absence of other factors potentially able to trigger AF. In all patients sinus rhythm was restored within 72 h and the follow-up did not show any cardiac damage. To the best of our knowledge, this side-effect has never been reported to occur after HDM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Olivieri, A., Corvatta, L., Montanari, M. et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 21, 1049–1053 (1998). https://doi.org/10.1038/sj.bmt.1701217
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701217
Keywords
This article is cited by
-
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation
Journal of Thrombosis and Thrombolysis (2021)
-
Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
Bone Marrow Transplantation (2019)
-
Cardiovascular Complications of Hematopoietic Stem Cell Transplantation
Current Treatment Options in Cardiovascular Medicine (2016)
-
Arrhythmias in the setting of hematopoietic cell transplants
Bone Marrow Transplantation (2015)
-
Cancer Chemotherapy and Cardiac Arrhythmias: A Review
Drug Safety (2015)